About BrainsGate
BrainsGate is a company based in Caesarea (Israel) founded in 2000. BrainsGate has raised $79.5 million across 5 funding rounds from investors including Medtronic, Boston Scientific and BNP Paribas. BrainsGate operates in a competitive market with competitors including Rapid Medical, CoAxia, Cerus Endovascular, Anaconda Biomed and Oxford Endovascular, among others.
- Headquarter Caesarea, Israel
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$79.5 M (USD)
in 5 rounds
-
Latest Funding Round
$14 M (USD), Series F
Dec 06, 2020
-
Investors
Medtronic
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BrainsGate
BrainsGate has successfully raised a total of $79.5M across 5 strategic funding rounds. The most recent funding activity was a Series F round of $14 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BrainsGate
BrainsGate has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Medtronic, Boston Scientific and BNP Paribas.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in tech and healthtech sectors through dedicated funds.
|
Locked | Locked | Locked | |
|
Growth capital is provided to mature MedTech companies by Agate.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage technologies companies
|
Locked | Locked | Locked |
Investor details for BrainsGate
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BrainsGate
Investment portfolio details for BrainsGate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BrainsGate
Detailed financials for BrainsGate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Brainsgate Comparisons
Peer comparison for BrainsGate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BrainsGate
BrainsGate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rapid Medical, CoAxia, Cerus Endovascular, Anaconda Biomed and Oxford Endovascular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurovascular interventional devices including distal access catheters are developed.
|
|
| Locked | Locked | Locked |
Catheter-based treatment for cerebral ischemia
|
|
| Locked | Locked | Locked |
Interventional neuroradiology devices are developed for minimally invasive aneurysm treatment.
|
|
| Locked | Locked | Locked |
Medical devices for mechanical thromboectomy and clot removal are developed.
|
|
| Locked | Locked | Locked |
Metallic mesh devices for brain aneurysms are developed.
|
|
| Locked | Locked | Locked |
A hybrid polymer-metal stent for brain aneurysms is developed.
|
Detailed competitors of BrainsGate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Brainsgate
Complete news archive for BrainsGate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BrainsGate
BrainsGate was founded in 2000 and raised its 1st funding round 5 years after it was founded.
BrainsGate is headquartered in Caesarea, Israel. It is registered at Caesarea, Haifa, Israel.
BrainsGate is a funded company, having raised a total of $79.5M across 5 funding rounds to date.
BrainsGate is developing a platform technology for electrical stimulation of the sphenopalatine ganglion (SPG), a nervous center known to increase cerebral blood flow. Focus application is acute ischemic stroke. Has developed an implantable electrode which can be activated through an external system temporarily attached to the patients cheek.
BrainsGate's top competitors include Rapid Medical, Fluid Biomed and Anaconda Biomed.
BrainsGate has 10 investors. Key investors include Medtronic, Boston Scientific, BNP Paribas, Teva Pharmaceuticals, and Elron Ventures.
The valuation of BrainsGate is $147M as of Dec 2020.